Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Alogliptin (Nesina) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• The information was derived from five systematic reviews/meta-analyses studies comparing alogliptin with other antidiabetic drugs, including canagliflozin, dapagliflozin, empagliflozin, sitagliptin, vildagliptin, omarigliptin, and saxagliptin among others.
• Adherence rates for DPP4 inhibitors like alogliptin were found suboptimal but consistent across the class; adherence at one year was around 56.9%, decreasing over time. Saxagliptin and alogliptin had more frequent switching within the class compared to others.
• In terms of renal outcomes and adverse events (AEs), no significant differences were observed between DPP4 inhibitors like alogliptin and placebo regarding eGFR changes or albuminuria progression. They also showed similar AE profiles without increased risk of all-cause mortality.
• Cardiovascular safety assessments revealed that DPP4 inhibitors do not increase major cardiovascular events (MACE), mortality, or heart failure risks except for saxagliptin, which posed a higher heart failure risk; thus indicating an overall neutral impact on cardiovascular health by drugs such as Nesina (alogliptin).
• Efficacy comparisons highlighted that while most DPP4 inhibitors significantly reduced HbA1c levels, effectively lowering fasting plasma glucose (FPG) and BMI, alogliptin did not show significant reduction in some cases. However, DPP4 inhibitors generally maintained weight neutrality without increasing the incidence of AEs when compared among themselves or against placebos.